

Research

Open Access

CX₃CL1 (fractalkine) and CX₃CR1 expression in myelin oligodendrocyte glycoprotein-induced experimental autoimmune encephalomyelitis: kinetics and cellular origin

Dan Sunnemark*^{†1}, Sana Eltayeb^{†2}, Maria Nilsson¹, Erik Wallström², Hans Lassmann³, Tomas Olsson², Anna-Lena Berg⁴ and Anders Ericsson-Dahlstrand¹

Address: ¹Department of Molecular Sciences, AstraZeneca R&D Södertälje, S-151 85 Södertälje, Sweden, ²Neuroimmunology Unit, Department of Clinical Neuroscience, Karolinska Institutet, S-171 76 Stockholm, Sweden, ³Neurological Institute, University of Vienna, Austria and ⁴Safety Assessment, AstraZeneca R&D Södertälje, S-151 85, Södertälje, Sweden

Email: Dan Sunnemark* - Dan.Sunnemark@astrazeneca.com; Sana Eltayeb - Sana.ELTayeb@cmm.ki.se; Maria Nilsson - Maria.Nilsson@astrazeneca.com; Erik Wallström - Erik.Wallstrom@cmm.ki.se; Hans Lassmann - hans.lassmann@univie.ac.at; Tomas Olsson - Tomas.Olsson@cmm.ki.se; Anna-Lena Berg - Anna-Lena.Berg@astrazeneca.com; Anders Ericsson-Dahlstrand - Anders.Ericsson-Dahlstrand@astrazeneca.com

* Corresponding author †Equal contributors

Published: 29 July 2005

Received: 03 May 2005

Journal of Neuroinflammation 2005, 2:17 doi:10.1186/1742-2094-2-17

Accepted: 29 July 2005

This article is available from: <http://www.jneuroinflammation.com/content/2/1/17>

© 2005 Sunnemark et al; licensee BioMed Central Ltd.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/2.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Background: Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system (CNS). It is associated with local activation of microglia and astroglia, infiltration of activated macrophages and T cells, active degradation of myelin and damage to axons and neurons. The proposed role for CX₃CL1 (fractalkine) in the control of microglia activation and leukocyte infiltration places this chemokine and its receptor CX₃CR1 in a potentially strategic position to control key aspects in the pathological events that are associated with development of brain lesions in MS. In this study, we examine this hypothesis by analyzing the distribution, kinetics, regulation and cellular origin of CX₃CL1 and CX₃CR1 mRNA expression in the CNS of rats with an experimentally induced MS-like disease, myelin oligodendrocyte glycoprotein (MOG)-induced autoimmune encephalomyelitis (EAE).

Methods: The expression of CX₃CL1 and its receptor CX₃CR1 was studied with *in situ* hybridization histochemical detection of their mRNA with radio labeled cRNA probes in combination with immunohistochemical staining of phenotypic cell markers. Both healthy rat brains and brains from rats with MOG EAE were analyzed. In defined lesional stages of MOG EAE, the number of CX₃CR1 mRNA-expressing cells and the intensity of the *in situ* hybridization signal were determined by image analysis. Data were statistically evaluated by ANOVA, followed by Tukey's multiple comparison test.

Results: Expression of CX₃CL1 mRNA was present within neuronal-like cells located throughout the neuraxis of the healthy rat. Expression of CX₃CL1 remained unaltered in the CNS of rats with MOG-induced EAE, with the exception of an induced expression in astrocytes within inflammatory

lesions. Notably, the brain vasculature of healthy and encephalitic animals did not exhibit signs of CX₃CL1 mRNA expression. The receptor, CX₃CR1, was expressed by microglial cells in all regions of the healthy brain. Induction of MOG-induced EAE was associated with a distinct accumulation of CX₃CR1 mRNA expressing cells within the inflammatory brain lesions, the great majority of which stained positive for markers of the microglia-macrophage lineage. Analysis in time-staged brain lesions revealed elevated levels of CX₃CR1 mRNA in microglia in the periplaque zone, as well as a dramatically enhanced accumulation of CX₃CR1 expressing cells within the early-active, late-active and inactive, demyelinated lesions.

Conclusion: Our data demonstrate constitutive and regulated expression of the chemokine CX₃CL1 and its receptor CX₃CR1 by neurons/astrocytes and microglia, respectively, within the normal and inflamed rat brain. Our findings propose a mechanism by which neurons and reactive astrocytes may control migration and function of the surrounding microglia. In addition, the accumulation of CX₃CR1 expressing cells other than microglia within the inflammatory brain lesions indicate a possible role for CX₃CL1 in controlling invasion of peripheral leucocytes to the brain.

Background

Chemokines are key mediators controlling infiltration of leukocytes to inflamed areas. They consist of a class of related proteins that exert chemotactic properties on leukocytes via interactions with select members of the G-protein coupled, cell membrane-spanning receptors (GPCRs). The so far 50 identified chemokines are divided into 4 subgroups, the XC, CC, CXC and CX₃C chemokines, and the corresponding GPCRs are accordingly denominated XCR (presently one member), CCR (11 orphanized members), CXCR (6 members) and CX₃CR (one single member). Synthesis of chemokines is rapidly induced in damaged or infected tissues and the cell-specific expression of chemokine receptors combined with the situation-specific production of their chemokine ligands provide cues to attract appropriate cell populations to combat invading organisms and neoplastic cells and to clear and repair damaged tissues. Chemokines are also thought to drive chronic inflammatory processes and this has fuelled hopes that pharmacological intervention of ligand-triggered activation of chemokine receptors may serve to reduce clinical manifestations in disorders with inflammatory components [1].

CX₃CL1 (alternative names: fractalkine or neurotactin) was identified in 1997 as a chemokine of 373 amino acids with, for the chemokine family, an atypical structure, a chemokine domain tethered on top of a mucin-like domain which is followed by a single transmembrane spanning domain and a short cytoplasmic tail [2-4]. CX₃CL1 is expressed within the brain, heart, lung, kidney, muscle and testis [4-8] where it interacts with a single GPCR, CX₃CR1 [9,10] to trigger chemotaxis and adhesion [10-13] of CX₃CR1 expressing cells, including neutrophils, monocytes, NK cells and Th-1 polarized T cells [10,14]. Studies of expression profiles, functional role in *in vitro* and *in vivo* systems and genetic associations to dis-

eases have provided promising clues to a potential role of CX₃CL1 and its receptor in, among others, rheumatoid arthritis [15-17], allograft rejections [18] and atherosclerosis [19-21].

The physiological role of CX₃CL1 and its receptor in the brain, however, is less clear. Expression of CX₃CL1 within the brain is localized to neurons [22-25], whereas CX₃CR1 is expressed by brain microglia [6,24-26]. Axotomy of the facial nerve trigger increased expression of CX₃CL1 among the severed motor neurons in the facial nucleus [6] and a similar response was recently observed following intraparenchymal injection of prion proteins [22]. Induction of experimental autoimmune encephalomyelitis (EAE; an animal model for multiple sclerosis) in the mouse has also been associated with CX₃CL1-like immunoreactivity in blood vessels within the inflammatory brain lesions [3]. This finding is complemented by the increased levels of CX₃CR1 mRNA in the spinal cord of rats with EAE, as demonstrated by RNase protection assay [27]. CX₃CL1 has moreover been shown to regulate microglia functions, including CX₃CL1-induced mobilization of intracellular Ca²⁺, chemotaxis and the inhibition of Fas-mediated apoptosis *in vitro* [6,23,28]. This is reflected in the activation of microglia following injection of CX₃CL1 *in vivo* to the rat brain parenchyma [22], indicating a potential role for CX₃CL1 and CX₃CR1 in mediating neuronal-microglial cross talk under normal and pathological conditions. In addition, previous claims of CX₃CL1 expression in endothelial cells [3,15,16,29-32], combined with CX₃CR1 on monocytes and Th-1 cells [5,14-16,33,34] may indicate a role in attracting pathogenic cells to sites of neuroinflammation, as well.

Multiple sclerosis (MS) is a chronic inflammatory disease of the CNS. It is associated with local activation of microglia and astroglia, infiltration of activated macrophages

and T cells, active degradation of myelin and damage to axons and neurons. The disease often develops from isolated self-limiting episodes with various neurological manifestations, including paralysis, to persistent, accentuated loss of neurological functions. The neuroinflammatory component of the disease is, at least in initial phases, thought to mediate important aspects of the clinical manifestations. The proposed role for CX₃CL1 in the control of microglia activation and leukocyte infiltration places this chemokine/receptor pair in a potentially strategic position to control key aspects in the pathological events that are associated with development of brain lesions in MS. In this study, we examine this hypothesis further by analyzing the distribution, kinetics, regulation and cellular origin of CX₃CL1 and CX₃CR1 mRNA expression in the CNS of rats with MOG-induced EAE. The expression of CX₃CL1 and its receptor was studied with *in situ* hybridization histochemical detection of their mRNA with radio labeled cRNA probes in combination with immunohistochemical staining of phenotypic cell markers. Our findings suggest that CX₃CL1 and its receptor may control aspects of the neuroinflammatory processes in MOG-induced EAE, and possibly also MS.

Methods

Animals

Inbred female DA.RT1^{av1} rats were obtained from B&K Sollentuna, Stockholm, Sweden. All rats were housed under specific pathogen-free conditions to keep the influence of additional environmental factors, beside immunization, as low as possible. Female DA rats 10–14 weeks of age (150–200 g) were used. All animal experiments were approved and performed in accordance with Swedish national guidelines.

Preparation of MOG

The N-terminal sequence of rat MOG (amino acids 1–125) was expressed in *Escherichia coli* and purified to homogeneity by chelate chromatography [35]. The purified proteins in 6 M urea were then dialyzed against PBS to obtain a preparation that was stored at -20°C.

Induction and assessment of EAE

Rats were anaesthetized with methoxyflurane and injected intradermally at the base of the tail with 0.2 ml inoculum, containing 20 µg recombinant rat MOG in saline, emulsified (1:1) with incomplete Freund's adjuvant (IFA; Difco, Detroit, MI). Rats were clinically scored and weighted daily from day 7 post-immunization (p.i.) until day 30 p.i. by two alternating investigators. The clinical scoring was as follows: 0 = no illness, 1 = tail weakness or tail paralysis, 2 = hind leg paraparesis, 3 = hind leg paralysis, 4 = complete paralysis, moribund state, or death. A disease remission was defined as an improvement in disease score from either 3 or 4 to 1, or from 2, 3 or 4 to 0 that was

maintained for at least 2 days consecutively. A relapse was defined as an increase in the clinical deficit of at least two points that lasted for at least 2 days.

Histopathology

Tissues were obtained from healthy, non-immunized rats or rats sampled on day 8, 13, 18, 21, 24, 29 and 40 p.i. Rats were deeply anaesthetized with methoxyflurane and subjected to perfusion via aorta with 4% paraformaldehyde. Organs were dissected out, routinely embedded in paraffin wax and sectioned at 5 µm. Histopathological evaluation was performed on transverse sections of the forebrain, midbrain, brainstem and 17 different rostro-caudal levels of the spinal cord, using hematoxylin and eosin (HE), Luxol fast blue/-periodic acid Schiff's (PAS) staining and Bielschowsky silver impregnation, to assess inflammation, demyelination, and axonal pathology, respectively [36,37].

Preparation of radioactively labeled cRNA probes

Preparation of radioactively labeled cRNA probes encoding rat CX₃CL1 and CX₃CR1 was carried out as previously described [38]. Briefly, antisense and sense cRNA probes were transcribed *in vitro* with T3 or T7 RNA polymerase in the presence of ³⁵S-uridine triphosphate (³⁵S-UTP; NEN – DuMedical, Sollentuna, Sweden). After removal of unincorporated nucleotides by Quick Spin columns (Boehringer -Mannheim, Indianapolis, IN), the specific activities of all the probes were 1–3 × 10⁹ dpm/ug. The CX₃CL1 and CX₃CR1 cRNA probes were transcribed from cDNA fragments cloned into pDP18 CU minus plasmid vector (Ambion, Austin, Texas). These cDNA fragments correspond to a 450 base pair cDNA fragment of rat CX₃CL1 (from 20–469 bp, GeneBank accession number AF030358) and a 882 base pair cDNA fragment of rat CX₃CR1 (GenBank accession number RN04808), respectively, and were generated by RT-PCR using sequence-specific oligonucleotide primers. The identities of the cloned cDNA fragments were finally confirmed by sequencing and database comparisons. Restriction enzymes and RNA polymerases were obtained from Promega (Madison, WI).

In situ hybridization and immunohistochemistry

To detect expression of CX₃CL1 and CX₃CR1 mRNA, *in situ* hybridization experiments were performed on sections from rat CNS. Hybridization and autoradiography were carried out as previously described [39]. Briefly, tissue sections were mounted on Superfrost plus slides (Super Frost Plus, Pittsburgh, USA) and dried under vacuum overnight after deparaffination in xylene, pre-treated in a microwave oven for 10 minutes at 97°C in 10 mM SSC (pH 6.0) and dehydrated in ethanol. As controls, radio labeled sense probes were transcribed in the sense orientation and hybridized to slides as processed in parallel. After application of 100 µl of hybridization solution

containing 10^6 cpm of the cRNA probes, the slides were cover slipped and incubated at 60°C for 16 to 20 hours. Slides were subsequently washed in $4\times$ standard saline citrate (SSC, pH 7.0), digested in 20 $\mu\text{g}/\text{ml}$ ribonuclease A solution at 37°C for 30 minutes, washed in decreasing concentrations of SSC, ending with $0.1 \times \text{SSC}$ for 30 minutes at 70°C .

To identify the cellular phenotypes of the $\text{CX}_3\text{CL1}$ or $\text{CX}_3\text{CR1}$ expressing cells, an immunohistochemical staining protocol was directly applied following the *in situ* hybridization step, as previously described [39]. The following monoclonal primary antibodies were used: an antibody specific for rat monocytes and macrophages (ED-1, Serotec, diluted 1/500) or an antibody reactive with glial fibrillary acidic protein (GFAP; G-A-5 diluted 1/20; Boehringer – Mannheim). Analysis for expression of $\text{CX}_3\text{CL1}$ or $\text{CX}_3\text{CR1}$ in neurons was performed, using an antibody reactive to a neuronal specific protein (NeuN [40]) diluted 1/100, Chemicon). Notably, as the NeuN antigen proved to be sensitive to the present conditions for combined labeling of mRNA and protein, we selected to compare the distribution of NeuN protein and $\text{CX}_3\text{CL1}$ or $\text{CX}_3\text{CR1}$ mRNA independently on consecutive tissue sections. A biotinylated sheep anti-mouse IgG antibody (Life Sciences) served as the secondary reagent, with the avidin biotin peroxidase (ABC) detection system (ABC Elite, Vector Laboratories). Finally, a biotinylated lectin (GSI-B4, Vector Laboratories) combined with the ABC detection system was used for the detection of vascular endothelial cells and macrophages and microglia in various stages of activation. Parallel tissue sections were incubated without primary antibody as control of specificity of the staining.

Quantification of $\text{CX}_3\text{CR1}$ mRNA-expressing cells in defined lesional stages

In a total of 5 brain sections from 4 rats in the relapse stage (days 21–45), 10 inflammatory lesions were selected and defined according to the stage of demyelinating activity as previously described [41]. Briefly, early active (EA) lesions were characterized by dense infiltrates of macrophages, lymphocytes and microglia. Myelin sheaths were in the process of disintegration and macrophages contained luxol fast blue (LFB)-stained myelin degradation products. Late active (LA) lesions were still densely populated by macrophages. Damaged myelin had been removed from the axons and macrophages contained PAS-positive myelin degradation products. Inactive completely demyelinated (DM) lesions showed no evidence of ongoing tissue destruction. Inflammatory cells were present, but macrophages did not display LFB or PAS staining. A single plaque usually contained two or more different stages of lesional activity (e.g. a central DM core surrounded by LA and EA areas). The region in the immediate vicinity of the

plaques, showing no microscopic signs of demyelination, was defined as periplaque white matter (PPWM). Representative regions outside lesions and PPWM areas were defined as normal white matter (NWM) and served as internal controls. Following *in situ* hybridization and GSI-B4 isolectin immunohistochemistry, the brain sections (3 from the cerebellum and pons, 1 from the frontal cortex, 1 from the thalamus) were captured with a Kappa DX-20 digital camera mounted on a Nikon E600 microscope. In each of the defined lesions, the total number of GSI-B4+ cells as well as the numbers of GSI-B4+ and GSI-B4- cells with positive hybridization signals for $\text{CX}_3\text{CR1}$ were counted in a standardized field of $1.9 \times 10^4 \mu\text{m}^2$. The intensity of the *in situ* hybridization signal was determined by counting areas of silver grains exceeding the mean background level (as measured over 30 similarly sized areas outside the cellular borders) + 11 SD (Access Analysis system, Euromed Networks). In total, 8 EA lesions, 8 LA lesions, 7 DM lesions, 8 PPWM areas and 9 NWM areas were included in the analysis. Data were statistically evaluated with ANOVA, followed by Tukey's multiple comparison test. A *P* value < 0.05 was considered to be statistically significant.


Imaging

Bright-field images were captured with a Kappa DX-30 digital camera mounted on a Leica microscope. Digital images were imported into Adobe Photoshop (v. 6.0), where they were adjusted to balance and optimize brightness, contrast, and sharpness. Individual files were exported to Canvas (v. 8.0) for assembly into plates, which were rendered at initial resolution of 300 dpi.

Results

Expression of mRNA encoding $\text{CX}_3\text{CL1}$ and its receptor in the normal rat brain and spinal cord

Radio labeled antisense cRNA probes transcribed from cDNA encoding rat $\text{CX}_3\text{CL1}$ (Fig. 1) and its receptor, $\text{CX}_3\text{CR1}$ (data not shown), were initially hybridized *in situ* to $5 \mu\text{m}$ tissue section obtained throughout the entire rat brain and spinal cord. In the forebrain, cells expressing high levels of $\text{CX}_3\text{CL1}$ mRNA were detected throughout the olfactory bulb, cerebral cortex, amygdala, globus-pallidus and thalamus (Fig. 1). These cells manifested, with few exceptions, a neuronal phenotype and co-distributed with cells staining positive for the pan-neuronal marker NeuN (exemplified in Fig. 5a, b at the spinal cord level). High levels of $\text{CX}_3\text{CL1}$ mRNA expression were also detected in all pyramidal cells within the hippocampal formation (Fig. 1). Significantly lower, but still clearly detectable, levels of $\text{CX}_3\text{CL1}$ mRNA were observed within all aspects of the hypothalamus (Fig 1), with neurons within the ventromedial nucleus displaying the strongest labeling. In the mesencephalon, pons, medulla oblongata and the spinal cord low to medium expression levels were

**Figure 1**

Distribution of CX₃CL1 mRNA expressing cells in the normal rat brain. Coronal sections sampled at regular intervals throughout the rostro-caudal extent of the normal rat brain hybridized with a ³⁵S-labeled antisense-cRNA probe encoding rat CX₃CL1. Cells expressing mRNA encoding the chemokine are visualized as accumulations of white silver grain in this microscopic darkfield illumination at low magnification. The letters in each subfigure refer to the approximate levels according to the Paxinos stereotaxic brain atlas [61]. The highest levels of CX₃CL1 mRNA were detected exclusively within the grey matter of the cerebral cortex (A:a, B:a, C:a, D:a), hippocampus (C:b), septum (B:c), thalamus (C:d) and striatum (B:e). Medium to low level expression was detected in the hypothalamus (C:f), pons (E:g), mesencephalon (D:h), medulla oblongata (not shown) and spinal cord (F:i). The cerebellum (E:j) was devoid of CX₃CL1 expression, except for a low level of expression in the deep cerebellar nuclei. Parallel sections hybridized with a sense-transcribed CX₃CL1 cRNA probe of equal specific activity did not reveal signals above background levels.

uniformly detected in neuronal-like cells. A notable exception was the cerebellum, where very low levels of expression were detected within granule and pyramidal cells whereas neuronal like cells in the deep cerebellar nuclei expressed CX₃CL1 mRNA at medium levels (Fig. 1).

Tissue sections hybridized in parallel with a radio labeled cRNA probe transcribed in the sense orientation did not reveal any hybridization signal above background levels (data not shown).

In addition to the expression of CX₃CL1 mRNA among neuronal-like cells within the rat brain and spinal cord, we also detected low-to medium expression of CX₃CL1 in a few, solitary cells dispersed throughout the white matter areas. These cells manifested a flattened, elongated morphology (data not shown) and were not positively stained in dual labeling experiments for CX₃CL1 mRNA with phenotypic markers for macrophages/microglia or astrocytes. No expression of CX₃CL1 mRNA was detected in cells associated with the cerebral vasculature and the meninges, including the endothelial cells themselves.

In consecutive tissue sections, *in situ* hybridization with a radio labeled antisense cRNA probe encoding rat CX₃CR1 revealed a low-to-medium expression within cells uniformly distributed throughout the entire neuraxis (data not shown). The morphology of these cells, as well as their positive labeling with GSI-B4 (*Griffonia simplicifolia* isolectin B4; stains microglia, macrophages and endothelial cells) identified them as being inactive microglia (data not shown). No detectable expression was observed over other cells, including neurons and perivascular and meningeal macrophages. Hybridization with a sense cRNA probe transcribed from the same cDNA did not reveal a signal above background levels (data not shown).

Expression of mRNA encoding CX₃CL1 and its receptor in the CNS of rats with MOG-EAE

To explore the role of CX₃CL1 and its receptor in the control of inflammatory cascades in MS, we examined their expression and regulation in the CNS of rats with MOG-induced EAE. In inbred DA rats, this disease manifested a mostly relapsing-remitting disease course with an initial paralytic episode, commencing around day 9–13 followed by a partial or complete remission and then a relapse of paresis (Fig. 2). In some rats the initial (acute) paresis progressed directly into a prolonged paralysis without any intervening remission of symptoms. In a minority of the rats the acute episode spontaneously resolved without further clinical signs of disease. The acute phase of paresis was characterized histopathologically by astroglial and microglial activation and perivascular and submeningeal infiltration of lymphocytes, macrophages and granulocytes. The inflammatory lesions were mostly confined to the spinal cord and, in some rats, the optic nerve and the cerebellar white matter. In rats that exhibited a clinical relapse the inflammation followed generally the pattern observed during the acute phase with submeningeal and perivascular lesions. However, the inflammatory reaction was often more extensive with numerous confluent lesions that covered substantial areas of the spinal white matter (Fig. 4), sometimes extending into the grey matter areas. Inflammatory lesions were at this stage closely associated with a marked demyelination as well as axonal degeneration and loss of axonal density.




Figure 2
Sampling of rats from various clinical stages of MOG-EAE. Female DA rats (n = 20) were immunized with mineral oil-emulsified MOG and evaluated daily for severity of paralysis. The arrows indicate selected time point at which subsequent kinetic analyses were performed. Rats (n ≥ 3/group) which conformed in the clinical score curve above were perfused transcardially, tissues were dissected out and subjected to histopathological analysis of encephalitis and distribution of CX₃CL1 and CX₃CR1 expressing cells.

There was a distinct transition in cellular composition observed within the inflammatory lesions, from predominantly lymphocytes and granulocytes in the acute phase lesions to an overwhelming presence of macrophages and microglia with only a few granulocytes throughout the inflammatory lesions during the clinical relapse. These phagocytic cells exhibited obvious signs of uptake and degradation of myelin components. This pattern of paresis and histopathological alterations was generally in accordance with previous studies [37,42], to which interested readers are referred for further details on the disease pathology.

For the following studies we selected rats that conformed to the typical relapsing-remitting disease phenotype (Fig. 2). *In situ* hybridization experiments revealed an uncompromised neuronal expression of CX₃CL1 mRNA throughout the entire CNS at all time points examined, except for a tendency to a reduced level of expression in grey matter regions which were notably infiltrated with inflammatory cells (data not shown). In addition, increased expression of CX₃CL1 mRNA was evident in a small number of non-neuronal cells within the inflammatory lesions. Double-labeling experiments showed those cells to stain positive for the astroglial marker glial fibrillary acidic protein, GFAP (Fig. 5). No hybridization signal above background levels was detected in cells staining




Figure 3

Distribution of CX₃CR1 mRNA expressing cells in spinal cord of EAE rats. *In situ* hybridization with a radiolabeled antisense cRNA probe encoding rat CX₃CR1 to coronal sections from the lumbar segment of spinal cord of rats with MOG-EAE. Cells expressing CX₃CR1 mRNA are visualized by darkfield illumination of the photoemulsion-dipped slides.

positive for GSI-B4 (e.g. macrophages/microglia and endothelial cells). Tissue sections hybridized in parallel with a sense-transcribed CX₃CL1 cRNA probes did not generate hybridization signals above background levels (data not shown).

In situ hybridization with an antisense cRNA probe for CX₃CR1 demonstrated a low, constitutive expression of the receptor in cells evenly distributed throughout the spinal cord of healthy, non-immunized control rats (n = 3) and presymptomatic rats (day 8 p.i, n = 3) (Fig. 3). The morphology and positive staining for GSI-B4 identified these cells as being inactive microglial cells. Rats examined at various stages following onset of clinically manifest MOG-induced EAE (day 13 p.i, acute phase, n = 3; day 18 p.i, remission phase, n = 3; day 21 p.i, early relapse phase, n = 3; day 24 p.i, mid relapse phase, n = 3; day 29 p.i, late relapse phase, n = 3) demonstrated a clear visual increase in CX₃CR1 mRNA levels per cell, as well as a notably increased density of CX₃CR1 mRNA expressing cells, within the inflammatory areas (Fig. 3 and 4). These aggregates of CX₃CR1 mRNA expressing cells were closely over-

lapping with the inflammatory lesions, being prominent in the perivascular and submeningeal lesions during the acute phase and with a few remaining lesions detectable during the remission phase. In rats examined at various time points of the relapse phase the aggregation of cells expressing high levels of CX₃CR1 mRNA closely followed the areas of expanding lesions. The great majority of the CX₃CR1 mRNA expressing cells were at all stages of disease positively stained with GSI-B4 isolectin as well as with the marker for active phagocytosis, ED-1. While all GSI-B4 positive, CX₃CR1 mRNA expressing cells in PPWM regions displayed abundant ramified processes identifying them as resident microglia, the morphology of the GSI-B4 positive, CX₃CR1 mRNA expressing cells within EA, LA and DM lesions was consistent with both macrophages and microglia in an activated, phagocytic state (Fig. 5). Occasional GSI-B4 negative, CX₃CR1 mRNA expressing cells were identified within the inflammatory lesions. These cells had rounded or slightly elongated nuclei and were of lymphocyte-like size. However, the great majority of lymphocytes within the lesions did not express CX₃CR1 mRNA (data not shown).




Figure 4
Sublesional distribution of CX₃CR1 expressing cells. Cellular infiltrations in the MOG-EAE rat brain (early relapse phase; day 21 post immunization) are observed with hematoxylin-eosin staining (upper left). Areas of active demyelination are revealed with Luxol fast blue/PAS staining (upper right). Actively phagocytosing cells are detected with immunohistochemical staining for ED-1 (lower left). This figure exemplifies the uneven distribution of CX₃CR1 mRNA expressing cells (lower right) within the inflammatory aggregates.

Quantification of CX₃CR1 mRNA-expressing cells in relation to the stage of demyelinating activity

To further characterize the distribution of CX₃CR1 mRNA expressing cells in MOG-induced EAE, we performed a quantitative analysis in defined time-staged lesions. The strongest expression of CX₃CR1 mRNA was found in LA areas, which contained a significantly higher density of silver grains per square unit compared to EA areas ($p < 0.05$), DM areas ($p < 0.05$), PPWM regions ($p < 0.001$) and NWM ($p < 0.001$) (Table 1, Figure 6a). In EA and DM areas, the expression of CX₃CR1 mRNA was significantly

higher compared to PPWM ($p < 0.001$) and NWM ($p < 0.001$). Although PPWM regions tended to show a higher density of silver grains per square unit compared to NWM, this difference was not statistically significant (Table 1, Figure 6a). The actual number of CX₃CR1 mRNA expressing cells was three-fold higher in lesional areas compared to PPWM and NWM but did not differ significantly between EA, LA and DM. The overwhelming majority of the CX₃CR1 mRNA expressing cells stained positive for GSI-B4 isolectin, identifying them as macrophages/microglia (Table 1, Figure 6b). Although not all GSI-B4+




Figure 5
Phenotyping of CX₃CL1 and CX₃CR1 expressing cells. CX₃CL1 mRNA expressing cells (upper left). Immunohistochemical staining for the neuronal marker NeuN (upper right) performed on a parallel tissue section. Dual staining for CX₃CL1 mRNA and the astrocyte marker GFAP (lower left). Combined staining for CX₃CR1 mRNA and the microglial marker GSI-B4 isolectin (lower right).




Figure 6
Quantification of CX₃CR1 mRNA expressing cells in defined lesional stages. (a) Density of silver grains (defined as areas exceeding the mean background + 11 SD) per square unit. (b) Number of CX₃CR1 mRNA-expressing cells positively stained with GSI-B4 isolectin. (c) Correlation between total number of GSI-B4 cells and intensity of *in situ* hybridization signal (density of silver grains per square unit).

cells expressed CX₃CR1 mRNA, there was a significant ($p < 0.0001$) correlation between the total number of GSI-B4+ cells and the density of silver grains per square unit (Table 1, Figure 6c).

Discussion

This study was designed to provide further insights into the mechanisms of proinflammatory cell trafficking into the CNS in MS. Our results show that the chemokine CX₃CL1 is expressed, and actively regulated, within inflammatory CNS lesions in rats with MOG-induced EAE, a rodent model of MS. In addition, we demonstrate that cells expressing the CX₃CR1 receptor, the majority of which are potentially pathogenic phagocytic cells (i.e. macrophages and/or microglia), are densely accumulating within the inflammatory lesions. This is consistent with the hypothesis for a role of CX₃CL1-CX₃CR1 in the local control of leukocyte infiltration into CNS lesions in MOG-EAE rats, and possibly also MS. The constitutive CX₃CL1 and CX₃CR1 expression by neurons and microglia, respectively, even in the healthy rat brain, indicates a potential mechanism whereby neurons control microglia functions in the intact brain tissue, as well.

Our present findings of constitutive expression of CX₃CL1 within the normal rat brain are in agreement with previous reports where CX₃CL1 mRNA [24,25,43] and protein [25,43] was demonstrated in most CNS neurons of healthy rats. Similar results have also been obtained in the mouse [4], rhesus monkey [25] and human [44] brain. It is interesting to note that the levels of CX₃CL1 mRNA differed greatly between different CNS regions, possibly indicating a more pronounced role for neuronal CX₃CL1 in many forebrain structures, i.e. cerebral cortex, hippocampus and striatum. Our demonstration that CX₃CL1 mRNA expression is induced in astrocytes within EAE lesions is novel although the data are in accordance with study of humans with HIV-associated dementia where CX₃CL1 immunoreactivity was detected in astrocytes [45]. Induced expression of CX₃CL1 in astrocytes was also observed following intraparenchymal administration of prion protein to the rat brain [22]. Co-cultivation of human astrocytes and HIV-infected macrophages also resulted in increased CX₃CL1 immunoreactivity in astrocytes [45] and stimulation of rat [23] and human [46] astrocytes with TNF- α and IL-1 β or INF- γ *in vitro* has been shown to up regulate CX₃CL1 mRNA levels. A recent immunohistochemical study of MS- and normal brain tissue demonstrates a constituent CX₃CL1 expression in astrocytes and an increased expression in human adult astrocyte cultures stimulated with pro-inflammatory cytokines, but fail to demonstrate an upregulation of CX₃CL1 in MS patients [47]. However, these data collectively indicate that astrocytes are capable of upregulating CX₃CL1 expression in inflamed or injured brain tissues.

Table 1: Quantification of CX₃CR1 mRNA expressing cells per square unit in rat EAE lesions (mean ± SEM)

	NWM	PPWM	EA	LA	DM
Density of silver grains* per $1.9 \times 10^4 \mu\text{m}^2$	39.4 ± 8.2	70.8 ± 7.2	220.3 ± 17.4 ^a	276.3 ± 14.8 ^b	208.4 ± 18.3 ^a
Total number of GSI-B4+ cells per $1.9 \times 10^4 \mu\text{m}^2$	11.0 ± 1.5	18.6 ± 1.6	65.3 ± 5.3 ^a	68.1 ± 3.3 ^a	59.8 ± 2.4 ^a
Number of GSI-B4+/CX ₃ CR1+ cells per $1.9 \times 10^4 \mu\text{m}^2$	5 ± 0.9	12.4 ± 1.3	46.1 ± 7.4 ^a	50.7 ± 3.3 ^a	46.0 ± 3.8 ^a
Number of GSI-B4-/CX ₃ CR1+ cells per $1.9 \times 10^4 \mu\text{m}^2$	0 ± 0	0 ± 0	0.8 ± 0.3	2.1 ± 0.7 ^a	0.8 ± 0.4

*Silver grains: defined as areas exceeding the mean background level + 11 SD

^aStatistically significant against NWM and PPWM

^bStatistically significant against NWM, PPWM, EA and DM

In contrast to the observed expression of CX₃CL1 in neurons and astrocytes, we were not able to confirm previous findings in EAE-afflicted mice [2] where endothelial immunoreactivity for CX₃CL1 was demonstrated within inflamed brain lesions. Our findings are corroborated by a recent study by Schwaeble et al. [25] in which no CX₃CL1 mRNA expression was detected within the endothelium of EAE rats and mice. Possible explanations for the contradictory results are differences in the sensitivity of the detection methods used or a potential non-specific, immunohistochemical cross-reactivity to other proteins within the endothelium in the study by Bazan et al. [2]. An alternative explanation would be if the secreted form of CX₃CL1, which is produced within the inflamed brain parenchyma by neurons and astrocytes, is transcytosed in an abluminal-to-luminal direction for presentation to blood leukocytes in a similar manner to what previously have been described for IL-8 and RANTES [48]. It is, however, important to note that endothelial cells outside the CNS have convincingly been demonstrated to express CX₃CL1 mRNA and protein [6,8,29-32]. CX₃CL1 expression by the brain endothelium, which may be below the detection limit of our assay, therefore remains a tantalizing possibility by which blood leukocytes may become attracted to migrate across the blood-brain barrier into inflammatory CNS lesions of MOG EAE rats.

Our present studies of CX₃CR1 expression in the rat brain confirm previous findings by Harrison et al [43], Nishiyori et al [24] and others by demonstrating that microglia express CX₃CR1 mRNA constitutively within the normal rat brain. These findings are also consistent with previous demonstrations that CX₃CL1 increases microglial migration [43], proliferation [49], survival [28], intracellular recruitment of calcium [43] and secretion of cytokines and metalloproteases [50]. In addition, we demonstrate that CX₃CR1 mRNA expressing cells are rapidly accumulating at high densities within the inflammatory CNS lesions of rats with MOG-induced EAE, confirming previous observations [41]. Interestingly, those cells amassed throughout most kinetic stages of the lesions, with the

most conspicuous densities detected in the late active stages. It is tempting to speculate about a down-regulatory role of CX₃CR1 expression in these late lesional stages, based on the possible induction of non-signaling CX₃CR1 receptors [51]. The overwhelming majority of the CX₃CR1 mRNA expressing cells within the lesional areas were phagocytic cells (i.e. macrophages and/or microglia) as demonstrated in double-labeling protocols with the GSI-B4 isolectin or the ED-1 antibody. However, a few additional, non-GSI B4 labeled, CX₃CR1 mRNA expressing cells were also detected within the CNS lesions. These cells may be speculated to correspond to infiltrating blood leukocytes, such as NK cells, $\gamma\delta$ T cells and/or terminally differentiated CD4⁺ and CD8⁺ T cells, which previously have been described to express CX₃CL1 receptors and/or to respond functionally upon CX₃CL1 stimulation [14,15,33,52,53]. However, the majority of the lymphocyte-like cells within the inflammatory lesions of the present rats did not express CX₃CR1 mRNA. Notably, no expression of CX₃CR1 mRNA was detected in GFAP-labeled astrocytes (data not shown) or neuronal-like cells. This contrasts to earlier findings of CX₃CR1-like immunoreactivity within neurons of a rat model for prion disease [22], in humans with HIV encephalitis [44] and in vitro cultivated hippocampal neurons [54]. Hulshof et al. [47] found weak to moderate neuronal CX₃CR1-like immunoreactivity in the cortical grey matter, depending on the tissue sample observed. Those data suggest that some populations of neurons may indeed have the capacity to express CX₃CR1 under certain conditions.

Our present data are thus consistent with a role for CX₃CL1 in the rat CNS, both during healthy and inflammatory conditions. The constitutive expression of CX₃CL1 and its receptor on neurons and microglia respectively demonstrates that this chemokine-receptor pair is not normally promoting inflammation. Their function may under these conditions possibly be inert but CX₃CL1, which is normally linked physically to the neuronal membrane via a spacer domain and a transmembrane spanning motif [2], may alternatively mediate a direct contact between neurons and neighboring microglia via

its proadhesive properties [2]. Microglia are highly reactive to insults to brain tissue and may inflict permanent damage if not kept in check. A CX₃CL1-mediated interaction between neurons and surrounding microglia may under healthy conditions provide a mechanism by which neurons subdue the proinflammatory and neurotoxic capacity of microglia. This notion is supported by recent findings from in vitro studies where CX₃CL1 inhibited neuronal death following the stimulation in vitro of cocultured microglia and hippocampal neurons with lipopolysaccharide, LPS [55]. In this study, CX₃CL1 was also demonstrated to inhibit LPS stimulated activation of microglia and associated TNF- α synthesis [55]. Moreover, endogenous CX₃CL1 has also been shown to inhibit the increased levels of TNF- α and 8-isoprostane in the hippocampus and cerebrospinal fluid following intracerebroventricular injections of LPS [56]. In another study, CX₃CL1 protected neurons in vitro from the neurotoxic properties of platelet activating factor or the HIV envelope protein, Tat [44]. In contrast, under conditions where neurons and their axonal and dendritic projections are injured, as is frequently the case in EAE and MS, CX₃CL1 is likely to be cleaved and released from the neuronal membrane by locally acting metalloproteases [57]. This would create a chemotactic gradient that, in combination with other locally active proinflammatory mediators, may subserve the extensive accumulation and activation of microglia within injured brain sites as observed in the present study. In addition, the soluble form of CX₃CL1 may also contribute to the infiltration of CX₃CR1-expressing leukocytes, including macrophages and effector T and NK cells. These cell types have crucial roles in EAE as mediators of tissue destruction and/or disease regulation [58]. A functional significance of the soluble CX₃CL1 / CX₃CR1-pathway is suggested by the present demonstration of CX₃CR1 expression in macrophage-like cells and a small fraction of lymphocyte like cells. Interestingly, concurrent studies have provided functional evidences that CX₃CR1 and its ligand serve as important mediators of inflammation and pathology in animal models models for atherosclerosis, transplant rejections, glomerulonephritis and stroke [12,19,29,59]. Studies in mice with targeted deletions of the CX₃CL1 or CX₃CR1 genes have, however, failed to provide information regarding a contributory function for this chemokine-receptor pair in EAE. CX₃CL1 $^{-/-}$ mice [60] or CX₃CR1 $^{-/-}$ mice [18] developed EAE in a manner not significantly deviating from wildtype mice. Furthermore, CX₃CR1 $^{-/-}$ mice did not manifest alterations in the microglia responses around injured/dying motor neurons in a peripheral axotomy model [53]. These studies suggest a redundant compensatory mechanism by other chemotactic factors or a more subtle role of this chemokine-receptor pair in these mouse models for MS. The aforementioned studies, which proposed a neuroprotec-

tive role for CX₃CL1, would also warrant a more thorough investigation of the long-term outcome as regards paralysis and neuronal injuries in EAE-challenged CX₃CL1, or CX₃CR1, deficient mice. A definite assignment of the role of CX₃CL1 and its receptor in normal and inflamed or injured CNS conditions will await conceptual testing in animal disease models using more informative tools such as selective immunoneutralizing antisera, peptide antagonists or non-peptidergic CX₃CR1 antagonists delivered at various stages of the disease.

Conclusion

- We have provided data to demonstrate constitutive and regulated expression of the chemokine CX₃CL1 and its receptor CX₃CR1 by neurons/astrocytes and microglia, respectively, within the normal and inflamed rat brain.
- Our findings propose a mechanism by which neurons and reactive astrocytes may control migration and function of the surrounding microglia.
- In addition, the accumulation of CX₃CR1 expressing cells other than microglia within the inflammatory brain lesions indicate a possible role for CX₃CL1 in controlling invasion of peripheral leucocytes to the brain.

Competing interests

The author(s) declare that they have no competing interests.

Authors' contributions

Design of studies (DS, SE, EW, TO, HL, AE-D), cloning of plasmid construct (AE-D), experimental induction of EAE and preparation of tissues (SE, DS, MN), in situ hybridization and immunohistochemical histochemical stainings (DS, MN), analysis of data (DS, SE, HL, A-LB, AED), writing/reviewing of manuscript (all authors). All authors have read and approved the final manuscript.

Acknowledgements

The study was supported by The Swedish Medical Research Council, The Swedish Strategic Funds, The Swedish Society for Neurologically Disabled and Montel Williams foundations.

References

1. Karpus WJ: **Chemokines and central nervous system disorders.** *J Neurovirol* 2001, **7**:493-500.
2. Bazan JF, Bacon KB, Hardiman G, Wang W, Soo K, Rossi D, Greaves DR, Zlotnik A, Schall TJ: **A new class of membrane-bound chemokine with a CX3C motif.** *Nature* 1997, **385**:640-644.
3. Pan Y, Lloyd C, Zhou H, Dolich S, Deeds J, Gonzalo JA, Vath J, Gosselin M, Ma J, Dussault B, Woolf E, Alperin G, Culpepper J, Gutierrezramos JC, Gearing D: **Neurotactin, a membrane-anchored chemokine upregulated in brain inflammation.** *Nature* 1997, **387**:611-617.
4. Rossi DL, Hardiman G, Copeland NG, Gilbert DJ, Jenkins N, Zlotnik A, Bazan JF: **Cloning and characterization of a new type of mouse chemokine.** *Genomics* 1998, **47**:163-170.
5. Foussat A, Coulomb-L'Hermine A, Gosling J, Krzysiek R, Durand-Gasselin I, Schall T, Balian A, Richard Y, Galanaud P, Emilie D: **Frac-**

- talkine receptor expression by T lymphocyte subpopulations and in vivo production of fractalkine in human.** *Eur J Immunol* 2000, **30**:87-97.
6. Harrison JK, Jiang Y, Wees EA, Salafra MN, Liang HX, Feng L, Belardinelli L: **Inflammatory agents regulate in vivo expression of fractalkine in endothelial cells of the rat heart.** *J Leukoc Biol* 1999, **66**:937-944.
 7. Lucas AD, Chadwick N, Warren BF, Jewell DP, Gordon S, Powrie F, Greaves DR: **The transmembrane form of the CX3CL1 chemokine fractalkine is expressed predominantly by epithelial cells in vivo.** *Am J Pathol* 2001, **158**:855-866.
 8. Muehlhoefer A, Saubermann LJ, Gu X, Luedtke-Heckenkamp K, Xavier R, Blumberg RS, Podolsky DK, MacDermott RP, Reinecker HC: **Fractalkine is an epithelial and endothelial cell-derived chemoattractant for intraepithelial lymphocytes in the small intestinal mucosa.** *J Immunol* 2000, **164**:3368-3376.
 9. Combadiere C, Salzwedel K, Smith ED, Tiffany HL, Berger EA, Murphy PM: **Identification of CX3CR1. A chemotactic receptor for the human CX3C chemokine fractalkine and a fusion coreceptor for HIV-1.** *J Biol Chem* 1998, **273**:23799-23804.
 10. Imai T, Hieshima K, Haskell C, Baba M, Nagira M, Nishimura M, Kakizaki M, Takagi S, Nomiyama H, Schall TJ, Yoshie O: **Identification and molecular characterization of fractalkine receptor CX3CR1, which mediates both leukocyte migration and adhesion.** *Cell* 1997, **91**:521-530.
 11. Fong AM, Robinson LA, Steeber DA, Tedder TF, Yoshie O, Imai T, Patel DD: **Fractalkine and CX3CR1 mediate a novel mechanism of leukocyte capture, firm adhesion, and activation under physiologic flow.** *J Exp Med* 1998, **188**:1413-1419.
 12. Haskell CA, Cleary MD, Charo IF: **Molecular uncoupling of fractalkine-mediated cell adhesion and signal transduction. Rapid flow arrest of CX3CR1-expressing cells is independent of G-protein activation.** *J Biol Chem* 1999, **274**:10053-10058.
 13. Haskell CA, Cleary MD, Charo IF: **Unique role of the chemokine domain of fractalkine in cell capture. Kinetics of receptor dissociation correlate with cell adhesion.** *J Biol Chem* 2000, **275**:34183-34189.
 14. Fraticelli P, Sironi M, Bianchi G, D'Ambrosio D, Albanesi C, Stoppacciaro A, Chieppa M, Allavena P, Ruco L, Girolomoni G, Sinigaglia F, Vecchi A, Mantovani A: **Fractalkine (CX3CL1) as an amplification circuit of polarized Th1 responses.** *J Clin Invest* 2001, **107**:1173-1181.
 15. Nanki T, Imai T, Nagasaka K, Urasaki Y, Nonomura Y, Taniguchi K, Hayashida K, Hasegawa J, Yoshie O, Miyasaka N: **Migration of CX3CR1-positive T cells producing type I cytokines and cytotoxic molecules into the synovium of patients with rheumatoid arthritis.** *Arthritis Rheum* 2002, **46**:2878-2883.
 16. Ruth JH, Volin MV, Haines GK 3rd, Woodruff DC, Katschke KJ Jr, Woods JM, Park CC, Morel JC, Koch AE: **Fractalkine, a novel chemokine in rheumatoid arthritis and in rat adjuvant-induced arthritis.** *Arthritis Rheum* 2001, **44**:1568-1581.
 17. Volin MV, Woods JM, Amin MA, Connors MA, Harlow LA, Koch AE: **Fractalkine: a novel angiogenic chemokine in rheumatoid arthritis.** *Am J Pathol* 2001, **159**:1521-1530.
 18. Haskell CA, Hancock WW, Salant DJ, Gao W, Csizmadia V, Peters W, Faia K, Fituri O, Rottman JB, Charo IF: **Targeted deletion of CX(3)CR1 reveals a role for fractalkine in cardiac allograft rejection.** *J Clin Invest* 2001, **108**:679-688.
 19. Lesnik P, Haskell CA, Charo IF: **Decreased atherosclerosis in CX3CR1-/- mice reveals a role for fractalkine in atherogenesis.** *J Clin Invest* 2003, **111**:333-340.
 20. McDermott DH, Halcox JP, Schenke WH, Wacławski MA, Merrell MN, Epstein N, Quyyumi AA, Murphy P: **Association between polymorphism in the chemokine receptor CX3CR1 and coronary vascular endothelial dysfunction and atherosclerosis.** *Circ Res* 2001, **89**:401-407.
 21. Moatti D, Faure S, Fumeron F, Amara Mel W, Seknadji P, McDermott DH, Debre P, Aumont MC, Murphy PM, de Prost D, Combadiere C: **Polymorphism in the fractalkine receptor CX3CR1 as a genetic risk factor for coronary artery disease.** *Blood* 2001, **97**:1925-1928.
 22. Hughes PM, Botham MS, Frenzel S, Mir A, Perry VH: **Expression of fractalkine (CX3CL1) and its receptor, CX3CR1, during acute and chronic inflammation in the rodent CNS.** *Glia* 2002, **37**:314-327.
 23. Maciejewski-Lenoir D, Chen S, Feng L, Maki R, Bacon KB: **Characterization of fractalkine in rat brain cells: migratory and activation signals for CX3CR1-expressing microglia.** *J Immunol* 1999, **163**:1628-1635.
 24. Nishiyori A, Minami M, Ohtani Y, Takami S, Yamamoto J, Kawaguchi N, Kume T, Akaike A, Satoh M: **Localization of fractalkine and CX3CR1 mRNAs in rat brain: does fractalkine play a role in signaling from neuron to microglia?** *FEBS Lett* 1998, **429**:167-172.
 25. Schwaebler WJ, Stover CM, Schall TJ, Dairaghi DJ, Trinder PK, Lington C, Iglesias A, Schubart A, Lynch NJ, Weihe E, Schafer MKH: **Neuronal expression of fractalkine in the presence and absence of inflammation.** *FEBS Lett* 1998, **439**:203-207.
 26. Boddeke EW, Meigel I, Frenzel S, Biber K, Renn LQ, Gebicke-Harter P: **Functional expression of the fractalkine (CX3C) receptor and its regulation by lipopolysaccharide in rat microglia.** *Eur J Pharmacol* 1999, **374**:309-313.
 27. Jiang Y, Salafra MN, Adhikari S, Xia Y, Feng L, Sonntag MK, deFiebre CM, Pennell NA, Streit WJ, Harrison JK: **Chemokine receptor expression in cultured glia and rat experimental allergic encephalomyelitis.** *J Neuroimmunol* 1998, **86**:1-12.
 28. Boehme SA, Lio FM, Maciejewski-Lenoir D, Bacon KB, Conlon PJ: **The chemokine fractalkine inhibits Fas-mediated cell death of brain microglia.** *J Immunol* 2000, **165**:397-403.
 29. Feng L, Chen S, Garcia GE, Xia Y, Siani MA, Botti P, Wilson CB, Harrison JK, Bacon KB: **Prevention of crescentic glomerulonephritis by immunoneutralization of the fractalkine receptor CX3CR1 rapid communication.** *Kidney Int* 1999, **56**:612-620.
 30. Garcia GE, Xia Y, Chen S, Wang Y, Ye RD, Harrison JK, Bacon KB, Zerwes HG, Feng L: **NF-kappaB-dependent fractalkine induction in rat aortic endothelial cells stimulated by IL-1beta, TNF-alpha, and LPS.** *J Leukoc Biol* 2000, **67**:577-584.
 31. Imaizumi T, Matsumiya T, Fujimoto K, Okamoto K, Cui X, Ohtaki U, Hidemi Y, Yoshida Y, Satoh K: **Interferon-gamma stimulates the expression of CX3CL1/fractalkine in cultured human endothelial cells.** *Tohoku J Exp Med* 2000, **192**:127-139.
 32. Robinson LA, Nataraj C, Thomas DW, Howell DN, Griffiths R, Bautch V, Patel DD, Feng L, Coffman TM: **A role for fractalkine and its receptor (CX3CR1) in cardiac allograft rejection.** *J Immunol* 2000, **165**:6067-6072.
 33. Nishimura M, Umehara H, Nakayama T, Yoneda O, Hieshima K, Kakizaki M, Dohmae N, Yoshie O, Imai T: **Dual functions of fractalkine/CX3C ligand I in trafficking of perforin+/granzyme B+ cytotoxic effector lymphocytes that are defined by CX3CR1 expression.** *J Immunol* 2002, **168**:6173-6180.
 34. Raport CJ, Schweickart VL, Eddy RL Jr, Shows TB, Gray PW: **The orphan G-protein-coupled receptor-encoding gene V28 is closely related to genes for chemokine receptors and is expressed in lymphoid and neural tissues.** *Gene* 1995, **163**:295-299.
 35. Amor S, Groome N, Lington C, Morris MM, Dornmair K, Gardinier MV, Matthieu JM, Baker D: **Identification of epitopes of myelin oligodendrocyte glycoprotein for the induction of experimental allergic encephalomyelitis in SJL and Biozzi AB/H mice.** *J Immunol* 1994, **153**:4349-4356.
 36. Kornek B, Storch MK, Weissert R, Wallstrom E, Stefferl A, Olsson T, Lington C, Schmidbauer M, Lassmann H: **Multiple sclerosis and chronic autoimmune encephalomyelitis: a comparative quantitative study of axonal injury in active, inactive, and remyelinated lesions.** *Am J Pathol* 2000, **157**:267-276.
 37. Storch MK, Stefferl A, Brehm U, Weissert R, Wallstrom E, Kerschensteiner M, Olsson T, Lington C, Lassmann H: **Autoimmunity to myelin oligodendrocyte glycoprotein in rats mimics the spectrum of multiple sclerosis pathology.** *Brain Pathol* 1998, **8**:681-694.
 38. Simmons DM, Arriza JL, Swanson LW: **A complete protocol for in situ hybridization of messenger RNAs in brain and other tissues with radiolabeled single-stranded RNA probes.** *J Histochem* 1989, **12**:169-181.
 39. Eltayeb S, Sunnemark D, Berg AL, Nordvall G, Malmberg A, Lassmann H, Wallstrom E, Olsson T, Ericsson-Dahlstrand A: **Effector stage CC chemokine receptor-1 selective antagonism reduces multiple sclerosis-like rat disease.** *J Neuroimmunol* 2003, **142**:75-85.
 40. Mullen RJ, Buck CR, Smith AM: **NeuN, a neuronal specific nuclear protein in vertebrates.** *Development* 1992, **116**:201-211.

41. Sunnemark D, Eltayeb S, Wallstrom E, Appelsved L, Malmberg A, Lassmann H, Ericsson-Dahlstrand A, Piehl F, Olsson T: **Differential expression of the chemokine receptors CX3CR1 and CCRI by microglia and macrophages in myelin-oligodendrocyte-glycoprotein-induced experimental autoimmune encephalomyelitis.** *Brain Pathol* 2003, **13**:617-629.
42. Weissert R, Wallstrom E, Storch MK, Stefferl A, Lorentzen J, Lassmann H, Linington C, Olsson T: **MHC haplotype-dependent regulation of MOG-induced EAE in rats.** *J Clin Invest* 1998, **102**:1265-1273.
43. Harrison JK, Jiang Y, Chen S, Xia Y, Maciejewski D, McNamara RK, Streit WJ, Salafranca MN, Adhikari S, Thompson DA, Botti P, Bacon KB, Feng LL: **Role for neuronally derived fractalkine in mediating interactions between neurons and CX3CR1-expressing microglia.** *Proc Natl Acad Sci U S A* 1998, **95**:10896-10901.
44. Tong N, Perry SW, Zhang Q, James HJ, Guo H, Brooks A, Bal H, Kinnear SA, Fine S, Epstein LG, Dairaghi D, Schall TJ, Gendelman HE, Dewhurst S, Sharer LR, Gelbard HA: **Neuronal fractalkine expression in HIV-1 encephalitis: roles for macrophage recruitment and neuroprotection in the central nervous system.** *J Immunol* 2000, **164**:1333-1339.
45. Pereira CF, Middel J, Jansen G, Verhoef J, Nottet HS: **Enhanced expression of fractalkine in HIV-1 associated dementia.** *J Neuroimmunol* 2001, **115**:168-175.
46. Yoshida H, Imaizumi T, Fujimoto K, Matsuo N, Kimura K, Cui X, Matsumiya T, Tanji K, Shibata T, Tamo W, Kumagai M, Satoh K: **Synergistic stimulation, by tumor necrosis factor-alpha and interferon-gamma, of fractalkine expression in human astrocytes.** *Neurosci Lett* 2001, **303**:132-136.
47. Hulshof S, van Haastert ES, Kuipers HF, van den Elsen PJ, De Groot CJ, van der Valk P, Ravid R, Biber K: **CX3CL1 and CX3CR1 expression in human brain tissue: noninflammatory control versus multiple sclerosis.** *J Neuropathol Exp Neurol* 2003, **62**:899-907.
48. Middleton J, Neil S, Wintle J, Clark-Lewis I, Moore H, Lam C, Auer M, Hub E, Rot A: **Transcytosis and surface presentation of IL-8 by venular endothelial cells.** *Cell* 1997, **91**:385-395.
49. Hatori K, Nagai A, Heisel R, Ryu JK, Kim SU: **Fractalkine and fractalkine receptors in human neurons and glial cells.** *J Neurosci Res* 2002, **69**:418-426.
50. Cross AK, Woodrooffe MN: **Chemokine modulation of matrix metalloproteinase and TIMP production in adult rat brain microglia and a human microglial cell line in vitro.** *Glia* 1999, **28**:183-189.
51. Chen S, Luo D, Streit WJ, Harrison JK: **TGF-beta1 upregulates CX3CR1 expression and inhibits fractalkine-stimulated signaling in rat microglia.** *J Neuroimmunol* 2002, **133**:46-55.
52. Al-Aoukaty A, Rolstad B, Giaid A, Maghazachi AA: **MIP-3alpha, MIP-3beta and fractalkine induce the locomotion and the mobilization of intracellular calcium, and activate the heterotrimeric G proteins in human natural killer cells.** *Immunology* 1998, **95**:618-624.
53. Jung S, Aliberti J, Graemmel P, Sunshine MJ, Kreutzberg GW, Sher A, Littman DR: **Analysis of fractalkine receptor CX(3)CR1 function by targeted deletion and green fluorescent protein reporter gene insertion.** *Mol Cell Biol* 2000, **20**:4106-4114.
54. Meucci O, Fatatis A, Simen AA, Miller RJ: **Expression of CX3CR1 chemokine receptors on neurons and their role in neuronal survival.** *Proc Natl Acad Sci U S A* 2000, **97**:8075-8080.
55. Zujovic V, Benavides J, Vige X, Carter C, Taupin V: **Fractalkine modulates TNF-alpha secretion and neurotoxicity induced by microglial activation.** *Glia* 2000, **29**:305-315.
56. Zujovic V, Schussler N, Jourdain D, Duverger D, Taupin V: **In vivo neutralization of endogenous brain fractalkine increases hippocampal TNFalpha and 8-isoprostane production induced by intracerebroventricular injection of LPS.** *J Neuroimmunol* 2001, **115**:135-143.
57. Chapman GA, Moores K, Harrison D, Campbell CA, Stewart BR, Strijbos PJ: **Fractalkine cleavage from neuronal membranes represents an acute event in the inflammatory response to excitotoxic brain damage.** *J Neurosci* 2000, **20**:RC87.
58. Hemmer B, Cepok S, Nessler S, Sommer N: **Pathogenesis of multiple sclerosis: an update on immunology.** *Curr Opin Neurol* 2002, **15**:227-231.
59. Soriano SG, Amaravadi LS, Wang YF, Zhou H, Yu GX, Tonra JR, Fairchild-Huntress V, Fang Q, Dunmore JH, Huszar D, Pan Y: **Mice deficient in fractalkine are less susceptible to cerebral ischemia-reperfusion injury.** *J Neuroimmunol* 2002, **125**:59-65.
60. Cook DN, Chen SC, Sullivan LM, Manfra DJ, Wiekowski MT, Prosser DM, Vassileva G, Lira SA: **Generation and analysis of mice lacking the chemokine fractalkine.** *Mol Cell Biol* 2001, **21**:3159-3165.
61. Paxinos G, Watson C: **The Rat Brain in Stereotaxic Coordinates.** 4th edition. Academic Press; 1998.

Publish with **BioMed Central** and every scientist can read your work free of charge

"BioMed Central will be the most significant development for disseminating the results of biomedical research in our lifetime."

Sir Paul Nurse, Cancer Research UK

Your research papers will be:

- available free of charge to the entire biomedical community
- peer reviewed and published immediately upon acceptance
- cited in PubMed and archived on PubMed Central
- yours — you keep the copyright

Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp

